NASDAQ$HLVX
HilleVax Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported full year financial results and highlighted recent company progress.
HilleVax reported financial results for the year ended December 31, 2023. The company had $303.5 million in cash, cash equivalents and marketable securities as of December 31, 2023. Net loss for the fourth quarter 2023 was $37.0 million.
- Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024.
- Enrollment for NEST-IN1 study completed in Q2 2023
- Cash, cash equivalents and marketable securities totaled $303.5 million as of December 31, 2023.
- Sean McLoughlin appointed as Chief Operating Officer in Q1 2024.
Headline financials
Revenue & EPS history
HilleVax · Revenue · Quarterly
$2.86M
Forward guidance
HilleVax expects topline safety and clinical efficacy data from NEST-IN1 in mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports · overlaid with Q4 2023
-3.3%
Avg return
Earnings day
-2.3%
Avg return
5 days after
-0.9%
Avg return
30 days after
22%
4 / 18 earnings
Positive
+7.9%
Q4 2024
Best reaction
-16.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.5% | +0.5% | +2.0% | |
| Q1 2025 | -1.0% | -5.6% | -6.7% | |
| Q4 2024 | +7.9% | -10.1% | +17.0% | |
| Q3 2024 | -2.6% | +1.6% | +2.6% | |
| Q2 2024 | -0.6% | +5.7% | +8.2% | |
| Q1 2024 | +2.7% | -3.0% | +0.2% | |
| Q4 2023 | -9.0% | -5.4% | -29.5% | |
| Q3 2023 | +1.5% | — | — | |
| Q2 2023 | -16.7% | — | — | |
| Q1 2023 | -1.2% | — | — | |
| Q4 2022 | -12.1% | — | — | |
| Q3 2022 | -8.2% | — | — | |
| Q3 2021 | -8.2% | — | — | |
| Q2 2021 | -6.5% | — | — | |
| Q2 2022 | -6.5% | — | — | |
| Q1 2022 | +0.0% | — | — | |
| Q1 2021 | +0.0% | — | — | |
| Q4 2021 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro